StockTipsArenaBeta

BUY Aurobindo Pharma — Prakash Gaba

BUYAurobindo Pharma

byPrakash GabaHorizon: NA (inferred Intraday)26 Aug 2026, 9:21 am ISTvia CNBC Awaaz.

Entry₹1,624Inferred
Target₹1,640
Total upside +0.99% (call closed)
Stop loss₹1,612-0.74% risk
At expiry₹1,619.326 Aug 2026, 3:05 pm
Expired-0.29%
Follow Prakash Gaba for new calls(20% target hit, 256 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 26 Aug 2026
2 supporting1 neutral1 opposing
Supports the BUY call (2)

Aurobindo Pharma Share Price Gains As USFDA Concludes Inspection At Subsidiary Lannett's Unit

NewsNdtv-Profit·24 Aug · 2d ago

(opens in new tab)

Aurobindo Pharma US FDA inspection ends with one observation at AuroPeptides facility

NewsCnbc-Tv18·21 Aug · 4d ago

(opens in new tab)
Neutral / worth noting (1)

Here's why these four pharma stocks are in focus today

NewsCnbc-Tv18·24 Aug · 2d ago

(opens in new tab)
Weighs against the BUY call (1)

Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA

NewsLivemint·24 Aug · 2d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.